文献速递免疫规划卫生政策与健康促进

欧洲疫苗路线图创新伙伴关系(IPROVE):对未来疫苗的愿景

Innovation Partnership for a Roadmap on Vaccines in Europe (IPROVE): A vision for the vaccines of tomorrow.
PubMed 文献 · Vaccine · 2018-02-01

IPROVE是2013年12月启动的FP7项目,汇集130余家产学研及监管利益相关方,围绕七大主题开展咨询,提出80余条建议,聚焦多学科研究、加速知识转化与欧洲疫苗生态协作,并强调疫苗实施规划与应对疫苗犹豫。

要点

  • IPROVE围绕疫苗研发、生产质控、基础设施等七大主题咨询,提出80余条建议。
  • 建议聚焦多学科研究促进创新、加速科学知识向技术创新转化及欧洲疫苗生态协作。
  • 咨询强调疫苗效果取决于实施规划,需更多理解并应对公众与医护人员的疫苗犹豫。

核心结论

  • IPROVE首次尝试构建疫苗领域的全面愿景,旨在帮助政策制定者和资助方确定短期和中长期成功所需的关键投资领域与技术。

研究设计与样本

  • IPROVE是2013年12月启动的FP7项目,汇集来自学术界、公共卫生机构、监管机构、产业界及中小企业的130余家公私利益相关方。
  • 咨询过程围绕七个主题:疫苗研发、生产与质量控制、基础设施、治疗性疫苗、中小企业需求、疫苗接受度及培训需求。

主要发现

  • 咨询小组提出80余条建议,主要聚焦于以多学科研究方式促进创新、加速科学知识向技术创新转化以及在欧洲疫苗生态内促进真正协作。
  • 咨询还强化了疫苗效果取决于实施规划这一事实,并认为需更多理解并应对公众与医护人员的疫苗犹豫。
  • 汇集广泛利益相关方参与IPROVE路线图工作增进了对其不同视角、需求和优先事项的相互理解。

局限性

  • IPROVE是构建疫苗领域全面愿景的首次尝试。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A clear vision for vaccines research and development (R&D) is needed if Europe is to continue to lead the discovery of next generation vaccines. Innovation Partnership for a Roadmap on Vaccines in Europe (IPROVE) is a collaboration between leading vaccine experts to develop a roadmap setting out how Europe can best invest in the science and technology essential for vaccines innovation. This FP7 project, started in December 2013, brought together more than 130 key public and private stakeholders from academia, public health institutes, regulators, industry and small and medium-sized enterprises to determine and prioritise the gaps and challenges to be addressed to bolster innovation in vaccines and vaccination in Europe. The IPROVE consultation process was structured around seven themes: vaccine R&D, manufacturing and quality control, infrastructure, therapeutic vaccines, needs of small and medium-sized enterprises, vaccines acceptance and training needs. More than 80 recommendations were made by the consultation groups, mainly focused on the need for a multidisciplinary research approach to stimulate innovation, accelerated translation of scientific knowledge into technological innovation, and fostering of real collaboration within the European vaccine ecosystem. The consultation also reinforced the fact that vaccines are only as good as their vaccine implementation programmes, and that more must be done to understand and address vaccination hesitancy of both the general public and healthcare professionals. Bringing together a wide range of stakeholders to work on the IPROVE roadmap has increased mutual understanding of their different perspectives, needs and priorities. IPROVE is a first attempt to develop such a comprehensive view of the vaccine sector. This prioritisation effort, aims to help policy-makers and funders identify those vaccine-related areas and technologies where key investment is needed for short and medium-long term success.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Medaglini D, De Azero MR, Leroy O, et al. Innovation Partnership for a Roadmap on Vaccines in Europe (IPROVE): A vision for the vaccines of tomorrow. Vaccine. 2018. PMID: 29395517. doi:10.1016/j.vaccine.2017.11.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。